TITLE

Link Between Alzheimer's and Vascular Dementia Holds Promise

PUB. DATE
October 1999
SOURCE
Worldwide Biotech;Oct99, Vol. 11 Issue 10, p2
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports that medications are being studied that are designed to treat Alzheimer's disease and vascular dementia and thus could help simplify the treatment of so-called `mixed dementia.' Cause of mixed dementia; Results of clinical trials of propentofylline that involved patients with vascular dementia; Costs of dementia.
ACCESSION #
2330925

 

Related Articles

  • Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type. Hossain, M.; Jhee, S.S.; Shiovitz, T.; McDonald, C.; Sedek, G.; Pommier, F.; Cutler, N.R.; Hossain, Mohammad; Jhee, Stanford S; Shiovitz, Thomas; McDonald, Craig; Sedek, Greg; Pommier, Francoise; Cutler, Neal R // Clinical Pharmacokinetics;2002, Vol. 41 Issue 3, p225 

    Objective: To investigate the bioavailability of rivastigmine, an approved therapy for patients with mild to moderate dementia of the Alzheimer's type, at the highest approved single dose of 6 mg.Design and Setting: Randomised, two-period crossover, single-centre,...

  • Cure for Alzheimer's by 2025? O'Connor, John // McKnight's Long-Term Care News;Apr2012, Vol. 33 Issue 4, p3 

    The article presents information on National Alzheimer's Plan which will cure dementia and Alzheimer's disease in the U.S. by 2025.

  • BACE1 Deficient Mice: Their Role in Drug Target Validation and Implications for Alzheimer's Disease Therapies. Vassar, Robert // Current Medicinal Chemistry - Immunology, Endocrine & Metabolic ;Mar2003, Vol. 3 Issue 1, p47 

    A large (and still growing) body of evidence suggests that the �-amyloid peptide (A�) is central to the pathophysiology of Alzheimer's Disease (AD) and may in fact initiate disease processes that lead to this intractable neurodegenerative disorder. Amyloid plaques composed of A�...

  • The Medicinal Metallochemistry of Alzheimer's Disease. Cherny, Robert A.; Masters, Colin L.; Bush, Ashley I. // Current Medicinal Chemistry - Immunology, Endocrine & Metabolic ;Mar2003, Vol. 3 Issue 1, p9 

    The brain is an organ which is at once enriched in transition metals and highly susceptible to oxidative stress. By virtue of its high affinity for copper the Alzheimer's amyloid protein (A�) is capable of catalytic generation of neurotoxic H2O2 while its aggregation and deposition are...

  • Caring for Persons With Dementia: A Palliative Approach. Panke, Jo Ann; Volicer, Ladislav // Approach: The Naval Safety Center's Aviation Magazine;July-Sep2002, Vol. 47 Issue 7, p143 

    Describes a palliative approach to caring patients with Alzheimer's disease and other progressive dementias. Treatment preferences or advanced directives; Treatment options; Elimination of inappropriate aggressive medical interventions; Intensive therapeutic intervensions; Pain management;...

  • PREVENTING COGNITIVE DECLINE WITH GPC. Kiefer, Dale // Life Extension;Jul2003, Vol. 9 Issue 7, p26 

    Reports on the effectiveness and safety of L-alpha glycerylphosphorylcholine in preventing full-blown dementia of Alzheimer's disease of vascular dementia. Potential therapeutic benefits of natural acetylcholine precursor compounds; Changes in aging brains; Measures of cognitive function.

  • Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial. Rosler, Michael // BMJ: British Medical Journal (International Edition);03/06/99, Vol. 318 Issue 7184, p633 

    Evaluates the effects of rivastigmine on the core domains of Alzheimer's disease (AD). Cognitive subscale of the AD assessment scale; Effects on activities of daily living; Tolerability and safety.

  • Galantamine improved cognition and global functioning in vascular dementia or Alzheimer disease with cerebrovascular disease. Larson, Eric // ACP Journal Club;Nov/Dec2002, Vol. 137 Issue 3, p102 

    Discusses research being done on the efficacy of galantamine in improving cognitive ability and global functioning in patients with probable vascular dementia or Alzheimer disease with cerebrovascular disease. Reference to study by T. Erkinjuntii and colleagues, published in the April 2002...

  • Better Access To Dementia Drugs.  // Australian Journal of Pharmacy;Jun2013, Vol. 94 Issue 1117, p22 

    The article focuses on changes brought by the Pharmaceutical Benefits Scheme (PBS) as per which, for Alzheimer disease several drugs were approved including rivastigmine, galantamine and memantine, and informs that the Australian government has deducted price of anti-dementia drugs.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics